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Abstract
Background: Cancer stem cells are thought to play a pivotal role in tumor maintenance, metastasis, tumor therapy
resistance and relapse. Hence, the development of methods for non-invasive in vivo detection of cancer stem cells is of
great importance.
Methodology/Principal Findings: Here,wedescribe successful invivo detection ofCD133/prominin, a cancerstemcell surface
markerfor a varietyoftumor entities. The CD133-specific monoclonalantibodyAC133.1was used for quantitativefluorescence-
based optical imaging of mouse xenograft models based on isogenic pairs of CD133 positive and negative cell lines. A first set
consisted of wild-type U251 glioblastoma cells, which do not express CD133, and lentivirally transduced CD133-overexpressing
U251 cells. A second set made use of HCT116 colon carcinoma cells, which uniformly express CD133 at levels comparable to
primary glioblastoma stem cells, and a CD133-negative HCT116 derivative. Not surprisingly, visualization and quantification of
CD133 inoverexpressing U251 xenografts was successful; more importantly, however, significant differenceswere also found in
matched HCT116 xenograft pairs, despite the lower CD133 expression levels. The binding of i.v.-injected AC133.1 antibodies to
CD133 positive, but not negative, tumor cells isolated from xenografts was confirmed by flow cytometry.
Conclusions/Significance: Taken together, our results show that non-invasive antibody-based in vivo imaging of tumor-
associated CD133 is feasible and that CD133 antibody-based tumor targeting is efficient. This should facilitate developing
clinically applicable cancer stem cell imaging methods and CD133 antibody-based therapeutics.
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Introduction
Many malignant tumors contain a subset of so-called cancer
stem cells (CSCs) with features similar to those of normal stem
cells. The frequencies of CSCs are found to vary from less than 1
to more than 25% of the cells in a tumor [1–3]. Cardinal features
of these stem-like cells are long-term self-renewal, tumorigenicity
upon xenotransplantation to immunocompromised mice, and a
certain differentiation capacity. Thus, xenotransplanted tumors
initiated by CSCs tend to reflect the cellular heterogeneity of the
original tumors. In contrast, more differentiated primary tumor
cells are less or completely non-tumorigenic in immunocompro-
mised mice [1,2]. There is growing evidence that CSCs drive
metastasis [1,4,5]. Moreover, they seem to be highly resistant to
chemotherapy and radiation and may thus be crucial in tumor
recurrence after conventional therapy. Resistance mechanisms
discussed include the expression of multidrug resistance transport-
ers, slow cycling, efficient repair of DNA damage and a high
expression of antiapoptotic proteins [6,7].
CSCs express stem cell-specific transcription factors such as
Sox2 as well as other intracellular stem- and progenitor cell
markers such as nestin, musashi, or aldehyde dehydrogenase [8].
More important for the identification of live CSCs, CSC-specific
surface markers have also been identified and major efforts are
ongoing to identify new markers. For example, human breast
CSCs appear to express a surface marker combination of lin-/
CD44hi/CD24low/-/ESA+ [8]. Another CSC marker found in a
multitude of tumor entities is CD133/prominin. Prominin-1
(CD133) was originally described in mouse embryos as a marker
for neuroepithelial progenitor cells [9], and in humans as the
AC133 antigen, a marker of hematopoietic stem and progenitor
cells recognized by the monoclonal antibody (mAb) AC133 [10].
CD133/prominin is a highly glycosylated transmembrane protein.
Stem cells are characterized by a set of glycosylation-dependent
epitopes in the extracellular portion of CD133 recognized by the
mAb AC133 (CD133/1) and the mAbs AC141 and 293C
(CD133/2). These epitopes are lost upon differentiation [11].
Meanwhile, CD133/prominin (AC133) has been identified as a
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ma and medulloblastoma, as well as for a variety of non-nervous
system tumors such as pancreatic, colon, bronchial, prostate,
ovarian and liver cancer, melanoma, and leukemia [12,13]. In
gliomas, the frequency of cells expressing CD133 (AC133)
increases with tumor grade [14]. CD133 (AC133)-positive CSCs
of a variety of tumor entities have been shown to be particularly
chemo- and radioresistant [4,15,16]. Thus as a putative CSC
marker for a wide variety of tumor entities, CD133 (AC133) is one
of the most intensively investigated of the known CSC markers.
In view of their above described essential role, non-invasive
imaging of CSCs would be of great value in the management of
malignant diseases; e.g., for determining prognosis, monitoring
therapeutic efficacy and influencing therapeutic protocols [17].
For noninvasive imaging of CSCs as well as CSC-specific
therapies, the targeting of cell surface proteins using antibodies
or other receptor ligands is particularly relevant [18]. Although
there are some recent reports of therapeutic targeting of CSC
marker-expressing tumor cells with mAbs [19–21], non-invasive in
vivo imaging of unmanipulated CSCs or CSC-marker expressing
tumor cells has not been reported thus far [17,22].
Our long-term goal is to develop antibody-based probes and
methods for the noninvasive imaging of CSCs in vivo, specifically of
CD133+ CSCs. However, CSCs may often constitute only a small
population of the cells in a tumor. Thus there is a need for imaging
modalities and probes that provide high sensitivity and high image
resolution [17]. Here, as a first step towards this goal, we assessed
whether it is possible to detect CD133 expressed on xenograft
tumors by noninvasive antibody-based in vivo imaging. For this
purpose, we used isogenic pairs of CD133 positive and negative
tumor cell lines as robust and reproducible tumor models with
defined intrinsic negative control. As an antibody, we employed
the mAb AC133, which is commercially available and is widely
used for enrichment and isolation of CD133+ CSCs [13]. Near-
infrared fluorescence molecular tomography (FMT), a highly
sensitive and fully quantitative technology, was employed as the in
vivo imaging modality [23,24].
Materials and Methods
Cell lines
HCT116 and HCT116 p532/2 colon carcinoma cells [25], as
well as the parental U251 glioma cells (ATCC, Manassas, VA,
USA) and a L1-CD133 lentivirus transduced CD133-overexpress-
ing U251 cell pool were cultured in DMEM (Invitrogen,
Darmstadt, Germany) with 10% FCS (PAA laboratories, Pasching,
Austria) supplemented with 1% penicillin/streptomycin (PAA
laboratories), 1x MEM non-essential amino acids (Invitrogen) and
2 mM L-glutamate (PAA laboratories). The primary glioblastoma
stem-like cells were generated from a glioblastoma sample of a
patient with primary glioblastoma multiforme (Firat et al., Delayed
cell death associated with mitotic catastrophe in c-irradiated stem-
like glioma cells. PLoS ONE, in revision) and were cultured in
Neurobasal-A medium (Invitrogen) supplemented with 20 ng/ml
epidermal growth factor and 20 ng/ml fibroblast growth factor
(from Prospec, Rehovot, Israel), 1% penicillin/streptomycin (PAA
laboratories), 0.5x MEM non-essential amino acids, 1x GlutaMax-
I (Invitrogen) and B27 supplement without vitamin A (Invitrogen).
Plasmids
The human CD133 full-length cDNA (IRAUp969F1267D) was
purchased from imaGenes (Berlin, Germany), and digested with
EcoRI. The CD133 ORF was then inserted into the EcoRI site of
the lentiviral vector L1-puro, which is a derivative of the
433_L1_myc_IRES_mitov#A65EA_cm5 [26] in which the GFP
was replaced by a puromycin resistance gene and the myc gene
was removed to create the L1-puro-CD133 lentiviral vector.
Lentiviral transductions
293T cells were co-transfected with the L1-puro-CD133
plasmid, pMD2.G (Addgene, Cambridge, MA, USA), which
encodes the VSV-G surface gene, and the pCMV8.74 vector
(Addgene), which provides the env and gag genes, using the
calcium phosphate method in the presence of 20 mM chloroquine
(Sigma-Aldrich, Seelze, Germany). Eight hours after transfection,
the medium was replaced by fresh DMEM. Lentiviral superna-
tants were harvested to transduce U251 cells in the presence of
5 mg/ml polybrene (Sigma-Aldrich) 36 and 60 h after transfection.
The transduced cells were selected using 1 mg/ml puromycin.
Antibodies
Anti-CD133/1 (AC133.1)-phycoerythrin (PE), anti-CD133/2
(293C3)-PE, and CD133/1 (W6B3C1) [10] were from Miltenyi
Biotec (Bergisch Gladbach, Germany), anti-mouse PE-conjugated
F(ab’)2-fragments from Dianova (Hamburg, Germany), and PE-
Cy7-conjugated anti-mouse CD11b from NatuTec (Frankfurt am
Main, Germany).
Antibody purification
The AC133.1 hybridoma cells (ATCC HB-12346) were
cultured in DMEM with Ultra low IgG FBS (Invitrogen). The
supernatant of a 250 ml culture was applied on a 5 ml protein G-
Sepharose column (GE Healthcare, Mu ¨nchen, Germany) and the
Sepharose was washed with PBS. The antibody was then eluted
using 100 mM glycine (pH 2.5), and the eluate immediately
neutralized using 1 M Tris-HCl (pH 8.8). The eluted antibody
was concentrated with Amicon Ultracel-50 k concentrators
(Millipore, Billerica, MA, USA) and dialysed against PBS. The
antibody concentration was determined by measuring the
absorbance at 280 nm using a NanoDrop ND-100 spectropho-
tometer (Peqlab, Erlangen, Germany).
Antibody labeling
Antibodies were labeled and purified using the Alexa-488
protein- or the Alexa-647 IgG-labeling kit (Invitrogen) according
to manufacturer’s protocols. Briefly, 1 mg AC133 antibody was
brought to a pH higher than 8.3 by adding 100 mM sodium
bicarbonate solution to a final volume of 0.5 ml. The antibody
solution was transferred to a vial of Alexa Fluor 488 reactive dye
and incubated at room temperature for 1 h in the dark. Labeled
antibodies were purified from free dye by gel filtration using a
column provided in the kit. Cy5.5 labeling was performed using
CyDye Cy5.5 mono-reactive NHS esters (GE Healthcare). A dye/
protein ratio of 2 to 3 dye molecules per antibody was first
determined by mixing 100 mg purified AC133 antibody with a
serial dilution of CyDye Cy5.5 mono-reactive NHS esters. For
large scale labeling, 1 mg purified AC133 antibody was incubated
with 60 mM CyDye Cy5.5 mono-reactive NHS ester in 100 mM
disodium hydrogen phosphate (pH 9) for 2 h. Labeled antibodies
were purified using a PD10 column (GE Healthcare).
Antibody titration and flow cytometry
Serially diluted antibody was incubated with 5610
5 CD133-
overexpressing U251 or HCT116 wild-type cells suspended in
100 ml of wash buffer (0.5% BSA/2 mM EDTA in PBS) for
15 min. After washing, the cells were incubated with 1.5 mgo fa n
anti-mouse PE-conjugated F(ab’)2-fragment in 100 ml wash buffer
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Cytomix FC-500 flow cytometer (Beckman Coulter, Krefeld,
Germany). Statistical analyses were performed using Graphpad
Prism 4.0b statistical software (GraphPad Software Inc., San
Diego, CA, USA).
Immunofluorescence microscopy
1610
6 HCT116 or HCT116 p532/2 cells were incubated in
wash buffer (see above) with 5 mg/ml AC133-Alexa647 antibody
for 20 min at 4uC. After washing with wash buffer, the cells were
fixed with 4% paraformaldehyde, and mounted onto slides in
Aqua PolyMount (Polysciences, Inc., Warrington, PA, USA)
supplemented with 1 mg/ml 4,6-diamidino-2-phenylindole (DAPI;
Roche, Basel, Switzerland). Pictures were taken using an Olympus
ScanR fluorescence microscope (Olympus, Hamburg, Germany).
Western blotting
Cells were lysed in RIPA buffer (1% NP40, 1% sodium
deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phos-
phate [pH 7.2], 2 mM EDTA, 50 mM sodium fluoride, 0.2 M
sodium orthovanadate) supplemented with the protease inhibitor
cocktail ‘Complete’ from Roche and proteins were quantified
using a BCA assay (Thermo Scientific, Bonn, Germany). 40 mg
lysate were applied to a 10% SDS gel and blotted onto a Hybond-
ECL membrane (GE Healthcare). CD133 antibody at a
concentration of 0.25 mg/ml was incubated for 3 h and detected
using a peroxidase-conjugated F(ab’)2-fragment goat anti-mouse
(Dianova). Actin antibody was incubated at a concentration of
0.25 mg/ml for 1 h and detected using a peroxidase-conjugated
F(ab’)2-fragment goat anti-rabbit (Dianova). The blots were
visualized by ECL (GE Healthcare).
Animal experiments
All animal experiments were performed in accordance with the
German Animal License Regulations and were approved by the
animal care committee of the Regierungspra ¨sidium Freiburg
(registration number: G-10/64). Subcutaneous (s.c.) xenografts
wereinducedinnude (NMRI-nu/nu) mice(Charles River,Sulzfeld,
Germany). 5610
6 U251 wild-type, CD133-overexpressing U251,
or HCT116 wild-type cells or 4610
6 HCT116 p532/2 cells were
injected per animal in 100 ml PBS. When the size of the tumor
reached 200–300 mm
3,75mg Cy5.5-labeledantibodiesand2 nmol
Integrisense 750 (PerkinElmer/Visen Medical, Bedford, MA, USA)
were injected via the tail vein, and the fluorescence signal was
visualized using a FMT1500 Fluorescence Molecular Tomography
system (PerkinElmer/VisEn Medical) at day 1, 2, 3, 4, and 7 for the
HCT116 xenografts and at day 1, 2, 4, and 7 for the U251
xenografts; 9 days after dye injection all mice were euthanized by
cervical dislocation and the isolated tumors were scanned with the
FMT system. For the determination of the lowest number of
HCT116 wild-type cells detectable by FMT, increasing percentages
(0, 20, 40, 60, 80, 100%) of HCT116 wild-type cells were mixed
with HCT116 p532/2 cells and stained with the AC133-Cy5.5
antibody in wash buffer (see above) for 30 min at 4uC. After
washing, 2610
6 cells were resuspended in 25 ml PBS, mixed with an
equal volume of matrigel, and injected s.c. into the flank of nude
mice. In vivo fluorescence signals were visualized using a FMT1500
within 1–2 h after tumor cell injection. After the experiment, all
mice were euthanized by cervical dislocation.
In vivo FMT imaging
Mice were anesthetized by gas anesthesia (isoflurane/oxygen
mixture), before placing them into an imaging cassette (PerkinEl-
mer/VisEn Medical). After positioning the cassette in the
FMT1500 imaging system (PerkinElmer/VisEn Medical), reflec-
tance images were captured in white light and fluorescence (2D
planar). For 3D imaging, a field around the tumor was selected,
and the tomographic scan was carried out. The scan data were
analyzed using reconstruction software provided by the manufac-
turer (PerkinElmer/VisEn Medical). For tomographic data
analysis, three-dimensional regions of interest (ROI) were drawn
around the tumor, and the total amount (in picomoles) of
fluorochrome was calculated by TrueQuant software (PerkinEl-
mer/VisEn Medical) using previously generated standards of the
appropriate dye.
Pre-tests for tumor digestion experiments
3610
6 HCT116 wild-type or HCT116 p532/2 cells grown in
10 cm dishes were incubated with 4 mg/ml AC133-Alexa488
antibody overnight. Cells were then washed with PBS and digested
with 0.7 U/ml Liberase-Blendzyme (Roche, Basel, Switzerland)/
Accutase (eBioscience, Frankfurt, Germany) for 50 min at 37uC.
After washing with 0.5% BSA/2 mM EDTA in PBS, the cells
were stained with 5 mg/ml of anti-CD133/2 (293C3)-PE and
analyzed by flow cytometry.
Tumor digestion
Tumor pieces were digested with 0.7 U/ml Liberase-Blend-
zyme (Roche)/Accutase (eBioscience)/100 U DNaseI (Invitro-
gen)/10 mM MgCl2 for 20 min at 37uC. Non-digested pieces
were further digested with accutase for 30 min. Red blood cells
were removed using RBC Lysis Buffer (eBioscience). Cells were
then washed with PBS, and suspended in wash buffer or a 2.4G2
hybridoma supernatant as an Fc blocker (for the CD11b staining
only). After 10 min, 5 mg/ml of anti-CD133/2 (293C3)-PE or
10 mg/ml of PE-Cy7-conjugated anti-mouse CD11b antibody was
added, and the cells were analyzed by flow cytometry.
Statistical Analysis
Results are presented as mean 6 SD. Data were compared
using the unpaired 2-tailed Student’s t test. A p-value ,0.05 was
considered significant (*: p,0.05 and **: p,0.01). Analyses were
performed using GraphPad Prism software version 4.0b (Graph-
Pad Software Inc., San Diego, USA).
Results
The AC133.1 mAb, which recognizes CD133 on tumor stem
cells, was chosen as a probe to detect CD133 expressing cells in
vivo. Besides a specific detection tool, a robust mouse model system
was required in order to develop a sensitive detection protocol. In
analogy to previously reported in vivo imaging studies, e.g.,
monitoring the epidermal growth factor receptor family [27], we
decided to generate a CD133-overexpressing cell line. To this end,
the CD133-negative U251 glioblastoma cell line was transduced
with a lentiviral construct encoding the full-length CD133 cDNA.
Flow cytometry analysis of these cells using the fluorescently
labeled AC133.1 antibody demonstrated an increase of antigen
expression by .100 fold compared to wild-type cells (Figure 1A,
upper panel). An isogenic CD133+/2 pair of HCT116 cell lines
served as an additional model system. Wild-type HCT116 colon
carcinoma cells uniformly express CD133 [28] at a level similar to
that found on primary glioblastoma stem-like cells. In stark
contrast, HCT116 p532/2 cells [25] were found to be virtually
CD133 negative (Figure 1A, lower panel). The flow cytometry data
were verified using immunostaining and a Western blot analysis
(Figures 1B and C).
In Vivo Imaging of CD133
PLoS ONE | www.plosone.org 3 December 2010 | Volume 5 | Issue 12 | e15605The relative surface CD133 expression levels of the positive cell
lines were determined measuring their AC133.1 antibody
saturation concentration via flow cytometry. The saturation point
for AC133.1 on CD133-overexpressing U251 cells was found to be
2.8610
28 M, and on HCT116 cells 5610
210 M, establishing the
CD133 expression level difference between HCT116 wild-type
cells and the CD133-overexpressing U251 cell line at ca. sixtyfold
(Figure 1D). Hence, the pair of wild-type and CD133-overex-
pressing U251 glioma cells was initially tested as a model system
for CD133 in vivo imaging.
In order to test whether the AC133.1 antibody could detect
CD133 expression in vivo, CD133-overexpressing and wild-type
U251 cells were subcutaneously (s.c.) implanted into nude mice
(for a tumor growth curve, see Figure S1). At a tumor size of 200 to
300 mm
3,7 5mg of Cy5.5-labeled AC133.1-antibody was injected
into the tail vein of each mouse, along with 2 nmol IntegriSense
750, and the resulting in vivo fluorescence signal was detected using
the FMT1500 after 1, 2, 4 and 7 days. IntegriSense 750 served as
an independent fluorescence marker to localize the tumor; it is an
optimized in vivo fluorescence imaging agent that targets integrin
alpha v beta 3, a key biomarker highly expressed on actively
angiogenic endothelium and certain types of tumor cells [29]. A
marked difference in AC133.1-Cy5.5-mediated fluorescence signal
intensities between wild-type and CD133-overexpressing U251
tumors was observed in the reflectance image (2D) as well as the
tomographic image (3D) (Figure 2A). A quantification of the
signals revealed a more than threefold higher AC133.1 antibody
concentration in the CD133-overexpressing U251 tumors com-
pared to the control tumors 7 days after antibody injection
(Figure 2B). The relative signal intensities between CD133-
overexpressing and negative cells remained fairly constant over
the course of the experiment, except that, toward the end, the
Figure 1. Characterization of cell lines and the AC133.1 antibody. (A) CD133 expression of HCT116, U251, and primary glioblastoma stem-
like cells as determined by flow cytometry. Upper panel: U251 wild-type cells and CD133-overexpressing U251 cell lines; lower panel: HCT116 wild-
type, HCT116 p532/2, and primary glioblastoma stem-like cells. Cells were incubated with the CD133/1-PE antibody and analyzed by flow
cytometry. The dotted lines show the unstained controls. (B) CD133 expression of HCT116 wild-type and HCT116 p532/2 cell lines as determined by
immunofluorescence microscopy. After incubation with the AC133-Alexa647 antibody, cells were counterstained with DAPI. (C) Levels of total cellular
CD133 protein as determined by Western blotting. Actin served as a loading control. (D) Determination of the saturation concentration of AC133.1
antibody for HCT116 wild-type or CD133-overexpressing U251 cells via flow cytometry. The cells were stained using serial dilutions of the purified
antibody and analyzed by flow cytometry using an anti-mouse PE-conjugated F(ab’)2 fragment. The saturation concentrations were determined using
prism software. WT, wild-type; OE, overexpressing.
doi:10.1371/journal.pone.0015605.g001
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control (Figure 2B). Scanning of the isolated tumors 9 days after
dye injection confirmed the in vivo results (Figure 2C).
Since imaging worked well using an overexpressing cell line, we
next tested whether the antibody could detect s.c. implanted
xenografts of HCT116 cells, which express CD133 at an
endogenous level. To this end, CD133-positive HCT116 wild-
type or CD133-negative HCT116 p532/2 cells were implanted
into nude mice (for a tumor growth curve, see Figure S1), and
similar experiments were performed as described above. Again,
the fluorescence intensities between the two cell lines differed
markedly, whether reflectance image (2D) or tomographic imaging
(3D) was used to analyze the signals (Figure 3A). A twofold higher
concentration of the AC133.1 antibody was detected in the
HCT116 wild-type tumors than in the CD133-negative HCT116
p532/2 tumors, 7 days after injection of the antibody (Figure 3B).
The relative signal intensities remained more or less constant over
the course of the experiment, with significant differences between
positive and negative tumors. Only at the first measurement 24 h
after antibody injection significant differences could not be
detected. The in vivo results could again be confirmed via imaging
of the isolated tumors (Figure 3C).
Although the signal differences between CD133-negative and -
positive tumors were statistically significant for both pairs of cell
lines used, the binding of the injected antibodies to their target still
had to be confirmed. Also, compared to the in vitro flow cytometry
results, the differences between CD133-negative and -positive cells
were far less pronounced in vivo, particularly in the case of the
U251 cells. Insufficient antibody injected, or an incomplete
penetration of the tumors by the antibody are possible explana-
Figure 2. In vivo imaging of U251 xenografts in mice injected with Cy5.5-labeled AC133.1 antibody. (A) U251 s.c. xenograft mice [U251
wild-type cells (lower panel) and CD133-overexpressing U251 cells (upper panel)] were injected with 75 mg AC133.1-Cy5.5 and 2 nmol of IntegriSense
750. One, 2, 4 and 7 days later, the mice were imaged using the VisEn FMT-1500 Fluorescence Molecular Tomography system. The pictures presented
correspond to the last measurement at day 7. (B) Quantification of AC133.1-Cy5.5 accumulation in U251 wild-type and CD133-overexpressing U251
xenografts. Signal intensity (pmol/mm
3) of the xenografts 7 days after AC133.1-Cy5.5 antibody injection (upper panel), and the resulting time course
over 7 days (lower panel). (C) Signal intensity of isolated tumors 9 days after AC133.1-Cy5.5 injection. Tumors were resected from mice and imaged
with an FMT-1500. WT, wild-type; OE, overexpressing.
doi:10.1371/journal.pone.0015605.g002
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signals. In order to address these issues, tumors were excised 3 days
after the injection of the Alexa488 labeled AC133 antibody and
single-cell suspensions were prepared. The single cell suspensions
were stained with a mAb recognizing another epitope of CD133
(CD133/2) [10], to obtain a measure of the total available CD133
molecules, and analyzed by flow cytometry. Previously performed
control experiments confirmed that the treatment of HCT116 cells
with accutase and blendzyme, the enzymes used for preparing
single-cell suspensions, did not remove cell-surface CD133 nor
bound AC133.1-Alexa488 antibodies (Figure 4A).
In single-cell suspensions of CD133-overexpressing U251
tumors, besides a large double positive population, cells positive
only for the in vitro added CD133/2 antibody were also detected,
indicating that the amount of injected antibody had not been
sufficient (Figure 4B, upper right panel). In contrast, in similar
preparations from CD133-positive HCT116 wild-type tumors
essentially all cells were double positive, suggesting that the
injected antibody had fully occupied the available CD133 epitopes
in vivo. However, the flow cytometry signals for both CD133
antibodies were rather low (Figure 4B, lower right panel).
A decrease of the CD133 expression levels in vivo might provide
an explanation for the apparently smaller difference in CD133
expression in vivo compared to in vitro. Indeed, when compared to
in vitro cultured cells, HCT116 wild-type cells isolated from
xenografts exhibited lower CD133 expression (Figure 4C).
We also found that a small population of CD133-negative cells
in the tumors bound injected AC133.1-Alexa488. In order to
determine whether these represent Fc-receptor-positive cells such
as macrophages, which bind antibodies via their Fc-portion,
Figure 3. In vivo imaging of HCT116 xenografts in mice injected with Cy5.5-labeled AC133.1. (A) HCT116 s.c. xenograft mice [HCT116
wild-type cells (upper panel) and HCT116 p532/2 cells (lower panel)] were injected with 75 mg AC133-Cy5.5 and 2 nmol of IntegriSense 750. One, 2,
3, 4 and 7 days later, the mice were imaged using the FMT-1500 system. The pictures presented correspond to the last measurement at day 7. (B)
Quantification of AC133.1-Cy5.5 accumulation in HCT116 and HCT116 p532/2 xenografts. Comparison of signal intensities (pmol/mm
3) between the
xenografts at day 7 after AC133.1-Cy5.5 injection (upper panel) and the time course over 7 days (lower panel). (C) Signal intensity of isolated tumors 9
days after AC133.1-Cy5.5 injection. Tumors were resected from mice and imaged with an FMT-1500 system. WT, wild-type.
doi:10.1371/journal.pone.0015605.g003
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CD11b. As shown in Figure 4D, a significant population of
CD11b-positive cells had indeed bound injected AC133.1 (double-
positive population in the left and right panel of Figure 4D).
Finally, the in vivo detection limit for HCT116 wild-type
cells was determined. For this purpose, CD133-positive HCT116
wild-type and CD133-negative HCT116 p532/2 cells were
mixed at ratios ranging from 0–100% wild-type cells, labeled with
AC133.1-Cy5.5 antibody in vitro, and injected s.c. into nude mice.
As shown in Figure S6, 1.6610
6 wild-type HCT116 cells in a 80%
wild-type (CD133+) to 20% p532/2 (CD133-) cell mix could
clearly be detected with the FMT1500.
Figure 4. Flow cytometric detection of i.v.-injected AC133.1-Alexa488 antibody on cells isolated from tumors. (A) Pre-test for tumor
digestion experiments showing that CD133 and prebound antibody can be detected after blendzyme/accutase digestion. HCT116 wild-type and
HCT116 p532/2 cells were incubated with AC133.1-Alexa488 overnight and digested with blendzyme/accutase for 50 min. The treated cells
were then stained with CD133/2-PE antibody and analyzed by flow cytometry. (B) Blendzyme/accutase digested tumors of AC133-Alexa488
injected mice were stained with CD133/2-PE antibody and analyzed by flow cytometry. (C) Downregulation of CD133 by s.c. growing HCT116
wild-type cells. Cells from digested tumors and in vitro cultured HCT116 cells were stained with CD133/2-PE antibody and CD133 expression levels
were determined by flow cytometry. The dotted lines show the unstained controls. (D) Tumor macrophages contribute to the signal of in vivo
injected AC133-Alexa488. Digested tumors were incubated with anti-mouse Fc-receptor blocking antibodies, stained thereafter with PE-Cy7-
CD11b antibody and analyzed by flow cytometry. In Figures 4A, B, and D, the percentages of cells falling into the negative, single- and double-
positive quadrants are shown. The quadrants were set according to the autofluorescence of the cells (for the gating controls and for statistical
analyses, see Figures S2, S3, S4, and S5). Due to the lower CD133 expression and lower antibody binding in vivo compared to in vitro,t h e
percentage of the cells in the different quadrants is difficult to precisely determine for HCT116 wild-type tumors but the shift towards the double-
positive quadrant of the majority of cells can clearly be seen (lower right panel in B; see also Figure S4). FL, fluorescence; WT, wild-type; OE,
overexpressing.
doi:10.1371/journal.pone.0015605.g004
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We present here results on the specific accumulation of a
fluorescently labeled AC133.1 mAb in CD133-positive xenograft
tumors detected by non-invasive in vivo fluorescence imaging.
These data provide the first evidence that non-invasive in vivo
imaging of tumor-associated CD133 (AC133), a well-known CSC-
marker, is feasible.
Relative to their negative counterparts, substantially higher
amounts of injected antibody were found on both CD133-
overexpressing U251 and HCT116 wild-type cells, the latter
expressing CD133 at endogenous levels similar to those of primary
CD133+ glioblastoma stem-like cells. The lower CD133 expres-
sion level of the HCT116 wild-type tumors led to a generally lower
signal to noise ratio compared to CD133-overexpressing U251
tumors. Thus, the difference in the AC133.1-Cy5.5-mediated
fluorescence signal between CD133-positive and -negative
HCT116 tumors reached statistical significance only after
48 hours, probably when injected antibodies had been cleared
from blood circulation. This slow ‘background clearing’ is often
observed in antibody-mediated in vivo imaging and is related to the
high molecular weight as well as the main clearance route via the
liver [30]. The lower signal to noise ratio of the HCT116 system
was further reduced by downregulation of CD133 expression in
vivo and non-specific antibody binding to tumor stroma macro-
phages. In the digested cell mix derived from the HCT116 wild-
type xenografts, macrophages with bound AC133 antibody
constituted less than 10% of antibody-bearing cells. However,
macrophages can represent . 50% of the cells in a tumor [31].
Although preventing Fc receptor binding might help to reduce the
background signals, the benefit of using small antibody fragments
lacking the Fc portion like Fab, F(ab)2, or single chain constructs
for in vivo imaging is contradictory [32]. Reasons are a lower
affinity in the case of monovalent fragments and lower tumor
uptake due to their fast excretion. The opposite is true for imaging
with mAbs, which have a very slow blood clearance rate. High
target affinity, sufficient tumor uptake due to better pharmacoki-
netics and reduced background due to diminished Fc receptor
binding may be achieved by engineering recombinant antibodies
or relatively large antibody fragments with a mutated Fc portion
[33].
Another problem encountered during our studies is the decrease
of CD133 expression in HCT116 tumor xenografts. A similar
observation has already been described for a melanoma cell line
[34]. Cells with CD133 expression lower than that of HCT116
wild-type cells may be hard to identify unequivocally with this
imaging method unless a proper negative control is available.
Moreover, tumor stem cells may represent only a small fraction of
the whole tumor; e.g., in glioblastomas, CD133 (AC133)-positive
cells range between 0 and 50% of the total cells [35]. With our
current method, 1.6610
6 cells in a mix containing 80% CD133-
positive wild-type cells could be detected. However, the detection
of CSCs in real tumors may be further complicated by the way
these cells are distributed within the tumor. Whereas a fraction of
CSCs may be concentrated in certain tumor regions (e.g., hypoxic
regions) or may occur in clusters [14], many CSCs are probably
spread throughout the tumor. Reliably imaging very low numbers
of scattered cells is very challenging. It requires probes providing
an exceptionally good signal-to-noise ratio, i.e., high-affinity
probes with fast tumor penetration, sufficient circulation time,
and low unspecific binding.
A homogeneous tumor penetration of the imaging probes is also
important since this is required to obtain reliable information on
the spatial distribution of CSCs within the tumor. Such topological
information would be important to optimize treatment planning,
e.g., in radiation therapy higher irradiation doses could be applied
to particularly resistant tumor subregions such as hypoxic or CSC-
rich regions by so-called ‘dose painting’ [36]. Homogeneous tumor
penetration would also be important for therapeutic targeting of
CSCs. Our study demonstrates that the AC133.1 antibody readily
finds its antigen in tumor xenografts in vivo, so it might be
worthwhile to derivatize the antibody with toxins [19], or use the
antibody to target liposomally encapsulated drugs.
Any potential diagnostic and therapeutic use of CD133-specific
antibodies in humans would require further investigations on the
expression pattern and level of CD133 epitopes in normal tissues
and the degree of specificity/cross-reactivities of available CD133-
specific mAbs. The AC133 and AC141 epitopes are expressed on
normal tissue stem and progenitor cells such as hematopoietic stem
and endothelial progenitor cells [10,37]. However, neural stem-
and progenitor cells in the stem cell-rich regions of the adult
human brain appear to be negative for these CD133 epitopes [38].
The epitopes seem to be expressed also on a subset of normal
tissue epithelial cells, but expression on normal tissue adjacent to
tumors has been described as being substantially lower than in the
malignant tumors studied [39]. If targeting CD133 (AC133)
should not prove specific enough for the detection of CSCs in situ
[40], possible solutions might include the identification of more
specific CSC-targets or the production of dual specificity
recombinant antibodies, i.e., with one arm specific for CD133
and the other for another CSC-antigen.
Taken together, our data provide first evidence that noninvasive
in vivo imaging of tumor-associated CD133 (AC133) is feasible. In
addition, they show that antibody-based targeting of CD133
(AC133) is efficient. However, additional efforts are still necessary
to characterize additional CSC markers, and to further develop
imaging probes and imaging modalities before a small population
of CSCs may be monitored reliably and noninvasively in vivo.
Supporting Information
Figure S1 Growth curves for U251 and HCT116 xeno-
graft tumors. Nude mice were injected s.c. with 5610
6 cells with
the exception of HCT116 p532/2 cells which were injected at a
numberof4610
6 to adjustthe growth rate to the HCT116 wild-type
tumors. Tumor sizes were measured twice weekly with a caliper.
Individual tumor volumes were calculated by the formula V=
[length 6(width)
2]/2. WT, wild-type; OE, CD133 overexpressing
(TIF)
Figure S2 Autofluorescence of the cells used for the flow
cytometric analyses presented in Figure 4A. The percent-
ages of cells falling into the negative, single- and double-positive
quadrants are shown. FL, fluorescence; WT, wild-type
(TIF)
Figure S3 Controls and statistics for the flow cytometric
analyses of the U251 tumors presented in Figure 4B. The
upper panels demonstrate the gating according to the autofluo-
rescence. Upper left subpanels: Autofluorescence of tumor cells
from ‘control mice’ that had not been injected with AC133.1-
Alexa488 antibody. Lower left subpanels: Fluorescence of tumor
cells from non-injected ‘control mice’ stained with a PE-labeled
CD133/2-specific antibody in vitro. Upper right subpanels:
Fluorescence of tumor cells from mice that had been injected
with AC133.1-Alexa488 antibody. Lower right subpanels: Fluo-
rescence of tumor cells from injected mice stained with a PE-
labeled CD133/2-specific antibody in vitro as shown in Figure 4B.
The lower two panels show a statistical analysis of the percentages
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fluorescence; WT, wild-type; OE, overexpressing
(TIF)
Figure S4 Controls and statistics for the flow cytometric
analyses of the HCT116 tumors presented in Figure 4B.
The upper panels demonstrate the gating according to the
autofluorescence. Upper left subpanels: Autofluorescence of tumor
cells from ‘control mice’ that had not been injected with AC133.1-
Alexa488 antibody. Lower left subpanels: Fluorescence of tumor
cells from non-injected ‘control mice’ stained with a PE-labeled
CD133/2-specific antibody in vitro. Upper right subpanels:
Fluorescence of tumor cells from mice that had been injected
with AC133.1-Alexa488 antibody. Lower right subpanels: Fluo-
rescence of tumor cells from injected mice stained with a PE-
labeled CD133/2-specific antibody in vitro as shown in Figure 4B.
The percentages of cells falling into the negative, single- and
double-positive quadrants are shown. The middle and the lower
panels show biological comparison controls (HCT116 wild-type vs.
HCT116 p532/2 xenograft cells). Middle panel: The red and the
black circled regions include the main cell population of a wild-
type and a p532/2 xenograft, respectively. These populations do
not overlap, demonstrating that the majority of the CD133+ cells
in the wild-type xenografts had bound the injected AC133.1-
Alexa488 antibody. Lower right panel: Statistical analysis of the
mean fluorescence intensities for the Alexa488 and the PE signal
(n=6 wild-type and 5 p532/2 tumors, respectively). The cell
populations analyzed fell into the gates shown in the lower left
panel. FL, fluorescence; MFI, mean fluorescence intensity; WT,
wild-type; OE, overexpressing
(TIF)
Figure S5 Controls and statistics for the flow cytometric
analyses presented in Figure 4D. Upper panels: Cells derived
from tumors of AC133.1-Alexa488-injected mice, but non-stained
with the CD11b-PE-Cy7 antibody (Cy7/FL5 autofluorescence).
Lower panel: Statistical analysis of the proportion of CD11b-
positive cells having bound the injected AC133.1-Alexa488
antibody (n=6). FL, fluorescence; WT, wild-type
(TIF)
Figure S6 Determination of the lowest number of
HCT116 wild-type cells detectable s.c. in vivo by FMT.
Increasing percentages of HCT116 wild-type cells were mixed
with HCT116 p532/2 cells and stained with the mAb AC133-
Cy5.5. The percentages of CD133-positive HCT116 wild-type
and CD133-negative HCT116 p532/2 cells were confirmed by
flow cytometry after staining with an anti-mouse PE-conjugated
F(ab’)2 fragment (middle panels); the single stain controls are
shown in the upper panels. After mixing with matrigel, 2610
6 cells
of these cell mixtures (in a total volume of 50 ml) were injected s.c.
into the flanks of nude mice. At the lower left, representative 2D
planar and 3D tomographic scans performed with an FMT1500
are shown. The injection sites of the cells are indicated by yellow
arrowheads, on the 2D image along with the percentages of the
CD133-positive HCT116 wild-type cells. In the 3D image, non-
specific signals detected from the interior of the body are indicated
by gray arrowheads. The panel at the lower right presents the
amount of Cy5.5 fluorochrome at the individual injection sites
(n=6 animals). WT, wild-type
(TIF)
Author Contributions
Conceived and designed the experiments: CT NE UE-B RG GN.
Performed the experiments: CT NE EF SG MF. Analyzed the data: CT
NE EF MF MB. Contributed reagents/materials/analysis tools: A-LG.
Wrote the paper: CT RG GN.
References
1. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, et al. (2009) Tumour-
initiating cells: challenges and opportunities for anticancer drug discovery. Nat
Rev Drug Discov 8: 806–823.
2. O’Brien CA, Kreso A, Dick JE (2009) Cancer stem cells in solid tumors: an
overview. Semin Radiat Oncol 19: 71–77.
3. Rosen JM, Jordan CT (2009) The increasing complexity of the cancer stem cell
paradigm. Science 324: 1670–1673.
4. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, et al. (2007)
Distinct populations of cancer stem cells determine tumor growth and
metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313–
323.
5. Lonardo E, Hermann PC, Heeschen C (2010) Pancreatic cancer stem cells -
update and future perspectives. Mol Oncol 4: 431–442.
6. Pajonk F, Vlashi E, McBride WH (2010) Radiation resistance of cancer stem
cells: the 4 R’s of radiobiology revisited. Stem Cells 28: 639–648.
7. Woodward WA, Bristow RG (2009) Radiosensitivity of cancer-initiating cells
and normal stem cells (or what the Heisenberg uncertainly principle has to do
with biology). Semin Radiat Oncol 19: 87–95.
8. Woodward WA, Sulman EP (2008) Cancer stem cells: markers or biomarkers?
Cancer Metastasis Rev 27: 459–470.
9. Weigmann A, Corbeil D, Hellwig A, Huttner WB (1997) Prominin, a novel
microvilli-specific polytopic membrane protein of the apical surface of epithelial
cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl
Acad Sci U S A 94: 12425–12430.
10. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, et al. (1997)
AC133, a novel marker for human hematopoietic stem and progenitor cells.
Blood 90: 5002–5012.
11. Kemper K, Sprick MR, de Bree M, Scopelliti A, Vermeulen L, et al. (2010) The
AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell
differentiation. Cancer Res 70: 719–729.
12. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al. (2003)
Identification of a cancer stem cell in human brain tumors. Cancer Res 63:
5821–5828.
13. Ferrandina G, Petrillo M, Bonanno G, Scambia G (2009) Targeting CD133
antigen in cancer. Expert Opin Ther Targets 13: 823–837.
14. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, et al. (2008) Stem
cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res
14: 123–129.
15. Chiou SH, Kao CL, Chen YW, Chien CS, Hung SC, et al. (2008) Identification
of CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor. PLoS
One 3: e2090.
16. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, et al. (2006) Glioma stem cells
promote radioresistance by preferential activation of the DNA damage response.
Nature 444: 756–760.
17. Hart LS, El-Deiry WS (2008) Invincible, but not invisible: imaging approaches
toward in vivo detection of cancer stem cells. J Clin Oncol 26: 2901–2910.
18. Okamoto OK, Perez JF (2008) Targeting cancer stem cells with monoclonal
antibodies: a new perspective in cancer therapy and diagnosis. Expert Rev Mol
Diagn 8: 387–393.
19. Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, et al. (2008) CD133/
prominin-1 is a potential therapeutic target for antibody-drug conjugates in
hepatocellular and gastric cancers. Br J Cancer 99: 100–109.
20. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, et al.
(2008) Identification of cells initiating human melanomas. Nature 451: 345–349.
21. Deonarain MP, Kousparou CA, Epenetos AA (2009) Antibodies targeting
cancer stem cells: a new paradigm in immunotherapy? MAbs 1: 12–25.
22. Vlashi E, Kim K, Lagadec C, Donna LD, McDonald JT, et al. (2009) In vivo
imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst 101:
350–359.
23. Ntziachristos V, Ripoll J, Wang LV, Weissleder R (2005) Looking and listening
to light: the evolution of whole-body photonic imaging. Nat Biotechnol 23:
313–320.
24. Montet X, Ntziachristos V, Grimm J, Weissleder R (2005) Tomographic
fluorescence mapping of tumor targets. Cancer Res 65: 6330–6336.
25. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, et al. (1998)
Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science
282: 1497–1501.
26. Tsurumi C, Firat E, Gaedicke S, Huai J, Mandal PK, et al. (2009) Viability and
DNA damage responses of TPPII-deficient Myc- and Ras-transformed
fibroblasts. Biochem Biophys Res Commun 386: 563–568.
In Vivo Imaging of CD133
PLoS ONE | www.plosone.org 9 December 2010 | Volume 5 | Issue 12 | e1560527. Ogawa M, Kosaka N, Choyke PL, Kobayashi H (2009) In vivo molecular
imaging of cancer with a quenching near-infrared fluorescent probe using
conjugates of monoclonal antibodies and indocyanine green. Cancer Res 69:
1268–1272.
28. Sureban SM, May R, George RJ, Dieckgraefe BK, McLeod HL, et al. (2008)
Knockdown of RNA binding protein musashi-1 leads to tumor regression in
vivo. Gastroenterology 134: 1448–1458.
29. Kossodo S, Pickarski M, Lin SA, Gleason A, Gaspar R, et al. (2009) Dual In
Vivo Quantification of Integrin-targeted and Protease-activated Agents in
Cancer Using Fluorescence Molecular Tomography (FMT). Mol Imaging Biol.
30. Wu AM, Senter PD (2005) Arming antibodies: prospects and challenges for
immunoconjugates. Nat Biotechnol 23: 1137–1146.
31. Pollard JW (2008) Macrophages define the invasive microenvironment in breast
cancer. J Leukoc Biol 84: 623–630.
32. Alt K, Wiehr S, Ehrlichmann W, Reischl G, Wolf P, et al. (2010) High-
resolution animal PET imaging of prostate cancer xenografts with three different
64Cu-labeled antibodies against native cell-adherent PSMA. Prostate 70:
1413–1421.
33. Olafsen T, Wu AM (2010) Antibody vectors for imaging. Semin Nucl Med 40:
167–181.
34. Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, et al. (2007)
Melanoma contains CD133 and ABCG2 positive cells with enhanced
tumourigenic potential. Eur J Cancer 43: 935–946.
35. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, et al. (2010)
A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer
Cell 17: 362–375.
36. Firat E, Heinemann F, Grosu AL, Frommhold H, Niedermann G (2010)
Molecular radiobiology meets clinical radiation oncology. Int J Radiat Biol 86:
252–259.
37. Mizrak D, Brittan M, Alison MR (2008) CD133: molecule of the moment.
J Pathol 214: 3–9.
38. Pfenninger CV, Roschupkina T, Hertwig F, Kottwitz D, Englund E, et al. (2007)
CD133 is not present on neurogenic astrocytes in the adult subventricular zone,
but on embryonic neural stem cells, ependymal cells, and glioblastoma cells.
Cancer Res 67: 5727–5736.
39. Fang DD, Kim YJ, Lee CN, Aggarwal S, McKinnon K, et al. (2010) Expansion
of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer
stem cell target discovery. Br J Cancer 102: 1265–1275.
40. Wu Y, Wu PY (2009) CD133 as a marker for cancer stem cells: progresses and
concerns. Stem Cells Dev 18: 1127–1134.
In Vivo Imaging of CD133
PLoS ONE | www.plosone.org 10 December 2010 | Volume 5 | Issue 12 | e15605